News

Thailand to begin its Covid-19 vaccine human trials in September

Bloomberg July 13 | Updated on July 13, 2020 Published on July 13, 2020

Thailand is starting the clinical stage for its own Covid-19 vaccine after both monkeys and mice generated satisfactory antibodies against the virus following injections, according to scientists in the study.

“We hope that the vaccine could generate neutralising antibodies in humans seen in monkeys and mice,” Kiat Ruxrungtham, head researcher at Chulalongkorn University’s Center of Excellence in Vaccine Research and Development, said at a briefing on Sunday in Bangkok. “If the trials are successful, Thailand could have its vaccine by the second half of 2021,” he said.

Equitable distribution needed

The Thai study will begin its human trials as early as September and will be among the first done outside high-income countries. Globally, 160 vaccines are being studied for Covid-19, of which 21 are at the clinical evaluation stage, according to the World Health Organization.

Access to life-saving vaccines is a perennial issue in poorer countries. The economic turmoil of the pandemic has raised the stakes, and the worry is that countries will compete for scarce supplies, seeking to protect their own populations. The Oslo-based Coalition for Epidemic Preparedness Innovations, WHO and the non-profit vaccine alliance Gavi are among those seeking equitable distribution.

Two groups

The first stage of Thai clinical trials will enrol about 100 volunteers separated in two groups, one for people aged 18 to 60 and the other for 60-80-year-olds, Kiat said. The focus of the first stage, which will take about two months, is on determining the safety and appropriate dosage for human use. The recruitment for volunteers is expected to start in September.

The second stage, likely to begin in December, will involve 500 to 1,000 people. The vaccine may get emergency-use authorisation from the Food and Drug Administration and skip the third and final stage, which would use more than 10,000 volunteers in countries with an ongoing outbreak, according to Kiat.

The Chulalongkorn University vaccine employs new mRNA technology, similar to that of a project led by Cambridge, Massachusetts-based Moderna Inc. The technique is cost-effective and ideal for large-scale production. Thailand also has several other Covid-19 vaccine studies underway using a variety of methods.

The production of 10,000 doses for the vaccine trials will start next week. Once the trials have completed all stages, Thailand will start output, with the potential to boost supplies for distribution to neighbouring nations and other low- or middle-income economies.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on July 13, 2020
This article is closed for comments.
Please Email the Editor